skip to main content

Colorectal Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersColorectal CancerSCE Medical Oncology

A patient with BRAF V600E-mutated metastatic colorectal cancer progresses after FOLFOX plus bevacizumab. There is no contraindication to anti-EGFR therapy. Which targeted regimen is recommended by NICE for this treatment position?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Encorafenib with cetuximab as the BRAF-EGFR targeted doublet

NICE TA668 recommends encorafenib with cetuximab after previous systemic treatment for BRAF V600E-mutated metastatic colorectal cancer. BRAF inhibition alone is limited by feedback activation of EGFR in colorectal cancer. Melanoma-style BRAF-MEK combinations are not the NICE-appraised colorectal regimen, and cetuximab alone does not adequately target the BRAF-driven pathway.

Reference: NICE TA668 encorafenib plus cetuximab for previously treated BRAF V600E metastatic colorectal cancer (Published January 2021): https://www.nice.org.uk/guidance/ta668/chapter/1-Recommendations